Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 17
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder [Corrigendum]
Authors Citrome L , Graham C, Simmons A, Jiang Y, Todtenkopf MS , Silverman B, DiPetrillo L, Cummings H, Sun L , McDonnell D
Received 22 September 2021
Accepted for publication 22 September 2021
Published 15 October 2021 Volume 2021:17 Pages 3135—3136
Citrome L, Graham C, Simmons A, et al. Neuropsychiatr Dis Treat. 2021;17:2885–2904.
The authors have advised there is an error in Figure 1C on page 2894. The key “OLZ/SAM” should read “Olanzapine + samidorphan 10 mg” and “Olanzapine” should read “Olanzapine + placebo”.
Figure 1 legend, the text “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12 in the combined OLZ/SAM groups (OLZ/SAM 5/10 mg, 10/10 mg, and 20/10 mg) versus olanzapine was the primary endpoint; only the olanzapine + placebo and olanzapine + samidorphan 10-mg groups are presented here to allow cross-study comparisons” should read “Panel (C) In ALK3831-302, antipsychotic efficacy, as measured by the change from baseline in the PANSS total score at week 12, was the primary endpoint comparing the combined olanzapine + samidorphan groups versus the olanzapine + placebo group; to allow cross-study comparisons, only the olanzapine + samidorphan 10-mg and the olanzapine + placebo groups are presented here”.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.